HIV and antiretroviral therapy disrupt the GHRH-GH-IGF1 peptide axis through two distinct mechanisms — suppressed GH in lipodystrophy and GH resistance in wasting — with the GHRH analog tesamorelin approved to treat the lipodystrophy form.
Tesamorelin: only FDA-approved GHRH analogApproved for HIV-associated lipodystrophy, it restores growth hormone pulsatility to reduce dangerous visceral fat accumulation caused by antiretroviral therapy
What the researchers found
Two distinct disruptions of the GHRH-GH-IGF1 axis occur in HIV/AIDS:
1. HIV lipodystrophy (associated with HAART): Suppressed GH production due to increased somatostatin tone, decreased ghrelin, elevated free fatty acids, and insulin resistance. Results in chronic inflammation, lipid abnormalities, and excess abdominal fat.
2. AIDS wasting syndrome: Elevated GH but low IGF-1 levels, indicating GH resistance — the body produces growth hormone but cannot respond to it properly.
Tesamorelin, a GHRH analog, is the only FDA-approved treatment for HIV-associated lipodystrophy, working by restoring GH pulsatility to reduce visceral adipose tissue.
Why it matters
HIV-associated lipodystrophy affects a significant proportion of people on antiretroviral therapy and carries real cardiovascular risk from excess visceral fat, insulin resistance, and lipid abnormalities. Understanding the peptide hormone mechanisms involved — somatostatin, ghrelin, GHRH, GH, and IGF-1 — explains why tesamorelin works and guides management of these metabolic complications.
How the study worked
This is a narrative review article summarizing the pathophysiology of growth hormone axis disruption in HIV/AIDS, drawing on published clinical and mechanistic research.
What this study cannot tell us
As a review article, this doesn't present original data. Published in 2013, some treatment paradigms and antiretroviral regimens discussed may have evolved. The review notes that long-term clinical data on tesamorelin was still needed at the time of writing. Individual patient responses to GH axis disruption vary significantly.
How to read the evidence
This is a review article summarizing established pathophysiology and clinical evidence. It synthesizes existing data rather than presenting new research, providing a strong educational overview.
When this study was published
Published in 2013, this review covers the foundational understanding of GH axis disruption in HIV. While core mechanisms remain valid, newer antiretroviral regimens and updated long-term tesamorelin data have since become available.
The bigger picture
Tesamorelin's approval in 2010 represented a milestone in peptide therapeutics — it's the only GHRH analog approved for clinical use. This review contextualizes why it works by explaining the specific peptide hormone disruptions in HIV lipodystrophy. The broader lesson is that understanding the precise mechanism of endocrine disruption is essential for choosing the right peptide-based intervention.
Questions still open
- Has long-term data on tesamorelin confirmed its cardiovascular safety in HIV lipodystrophy patients?
- Could newer antiretroviral regimens cause less growth hormone axis disruption than older HAART protocols?
- Would GH secretagogues or ghrelin agonists offer alternative approaches to treating HIV lipodystrophy?
Common questions
Why does HIV treatment cause belly fat accumulation?
How does tesamorelin work differently from regular growth hormone?
Read the original research
Pathophysiology of GHRH-growth hormone-IGF1 axis in HIV/AIDS.
Reviews in endocrine & metabolic disorders, 14(2), 113-8
Citation
Jain, Shobhit; Desai, Ninad; Bhangoo, Amrit. (2013). Pathophysiology of GHRH-growth hormone-IGF1 axis in HIV/AIDS.. Reviews in endocrine & metabolic disorders, 14(2), 113-8. https://doi.org/10.1007/s11154-013-9245-9